FDA Clears Edwards’ Non-Invasive Hemodynamic Monitor For High-Risk Surgical Patients
This article was originally published in The Gray Sheet
Executive Summary
ClearSight is intended to reduce the risk of post-surgical complications by non-invasively monitoring blood volume and flow based on information gathered by a small finger cuff with an infrared sensor.
You may also be interested in...
News In Brief
Edwards Lifesciences buys BMEYE for $42 mil. Sapien valve sales in Q3 fall below firm’s expectations. Hospira draws FDA warning letter. More news briefs.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.